ReviewCancer cell international2026
Reshaping the colorectal cancer immune microenvironment: insights from single-cell and spatial omics.
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- The microbiota-NK cell axis in colorectal cancer: a spatial and subset-centric framework.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a significant global health challenge, ranking among the leading causes of cancer-related morbidity and mortality. Accumulating evidence indicates that disease progression and therapeutic resistance in CRC are not solely tumor cells but are critically shaped by the tumor microenvironment (TME), including immune and stromal compartments and the extracellular matrix. Recent advances in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have enabled the integration of cellular identity with spatial context, thereby defining spatial niches and interaction networks that modulate both antitumor immunity and tumor-promoting programs in CRC. This review synthesizes scRNA-seq and spatial transcriptomic studies of CRC to characterize cellular heterogeneity and to delineate spatial niche organization and functional crosstalk within the TME. Building on these insights, we summarize emerging therapeutic perspectives in CRC, including rational combination immunotherapy strategies and promising targets such as SPP1⁺ tumor-associated macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.